Displaying drugs 14176 - 14200 of 15100 in total
NM-702
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans.
M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis,...
Investigational
Matched Description: … M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. ... Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis ... claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and …
XL765
XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
Investigational
Matched Description: … shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and …
IDM-2
IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Investigational
Matched Description: … from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and …
ANX-510
ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU). CoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer.
Investigational
Matched Description: … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce …
IRX-5183
Investigational
IDD552
Experimental
RO-4584820
Investigational
3,6-dihydroxy-xanthene-9-propionic acid
Experimental
5-Chloryl-2,4,6-quinazolinetriamine
Experimental
Ganstigmine
Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.
Investigational
2-[(2-methoxy-5-methylphenoxy)methyl]pyridine
Experimental
4-[(5-methoxy-2-methylphenoxy)methyl]pyridine
Experimental
2,3-Dihydroxy-Benzoic Acid
Experimental
N-Benzyl-4-Sulfamoyl-Benzamide
Experimental
2-methyl-5-methylidenepyrimidin-4-imine
Experimental
Dihydrouracil
Experimental
Isopropyl beta-D-thiogalactopyranoside
A non-metabolizable galactose analog that induces expression of the LAC operon.
Experimental
1,4-dithio-alpha-D-glucopyranose
Experimental
2-deoxy-2-acetamido-beta-D-galactose-4-sulfate
Experimental
Sucrosofate
Experimental
alpha-D-glucose 6-phosphate
Experimental
Displaying drugs 14176 - 14200 of 15100 in total